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Summary We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro.
As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement
killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1
cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization
of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of
membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in
suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in
suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two
systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and
C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in three-
dimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model
for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement.
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Nucleated cells, and tumour cells in particular, are resistant to
complement (C)-mediated killing (Vogel, 1991). The resistance is to
a great extent mediated by C-regulatory proteins and cell membrane
repair mechanisms (Morgan and Meri, 1994). The C-regulatory
proteins act atcritical steps in the C pathways. They interfere during
the C3/C5 convertase stage or restrict formation of the terminal
cytolytic membrane attack complex (MAC) (Morgan and Meri,
1994). Decay-accelerating factor (DAF, CD55) (Nicholson-Weller
et al, 1982; Pangburn et al, 1983) and complement receptor 1 (CR1,
CD35) (Fearon, 1979) directly inhibit the formation and promote
decay of the C3/C5 convertases of both classical and alternative
pathways. CR1 (Fearon, 1979) and membrane co-factor protein
(MCP, CD46) (Seya et al, 1986) act indirectly by serving as co-
factors for the enzymatic degradation of C3b or C4b. Homologous
restriction factor (HRF) (Zalman et al, 1986) or C8 binding protein
(C8bp) (Schonermark et al, 1986) and protectin (CD59) (Sugita et
al, 1988) regulate the formation and function of MAC. While
HRF/C8bp awaits detailed molecular characterization, the
processed cell surface form of CD59 is known to have 77 amino
acids (Fletcher et al, 1993) linked to the cell membrane via a
glycosyl-phosphatidylinositol (GPI) anchor (Stefanova' et al, 1989).
CD59 inhibits C lysis by interacting with C8 and C9 in the nascent
MAC and thereby restricting the number and polymerization ofC9
molecules in the complex (Meri et al, 1990; Rollins and Sims,
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1990). By preventing membrane insertion of C9 molecules, CD59
effectively blocks the formation of ion-permeable transmembrane
channels on the surface ofhuman cells (Meri et al, 1990).
We have recently observed that the C regulators MCP, DAF and
CD59 are expressed on ovarian carcinoma cells in vivo and in
vitro, and that DAF and CD59 appear to be the main factors in
protecting malignant ovarian cells against C-mediated killing
(Bj0rge et al, 1996). As a tumour arising from a 'non-essential'
organ that remains primarily confined to the peritoneal cavity,
ovarian cancer is particularly well suited for monoclonal antibody
(MAb) adjuvant immunotherapy (Rubin, 1993). Numerous clin-
ical antibody treatment trials have, unfortunately, failed to lead
to any consistent pattern of clinical response (Hamilton et al,
1987; Goodman et al, 1990; Guadagni et al, 1993; Rubin, 1993).
Consequently, the cells' ability to resist C attack may at least
partly explain the lack oftherapeutic efficiency oftumour-specific
MAbs (Bj0rge et al, 1996). If ovarian malignant cells are to be
killed by tumour-specific MAbs and C, the selected MAbs have to
be efficient activators of C and the cells' resistance to C has to be
overcome.
Most in vitro studies on the expression and function of C regu-
lators on malignant cells have used cell suspensions and/or mono-
layer cell cultures (Cheung et al, 1988; Bj0rge et al, 1994;
Hakulinen and Meri, 1994; Junnikkala et al, 1994; Brasoveanu et
al, 1995; Maenpaa et al, 1996). In many respects, these systems
are markedly different from the actual conditions in solid tumours
in vivo (Miiller-Klieser, 1987). As the vulnerability of cells to C
depends on their interaction with the microenvironment, the prop-
erties and functions of C-regulatory mechanisms in three-dimen-
sional systems may differ from those observed in two-dimensional
systems.
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Tumour cell microspheroids (TMSs) are widely used in in vitro
models of tumour nodules (Sutherland, 1988; Carlsson and
Nederman, 1992). Like tumour cells in vivo, cells in these spherical
aggregates are exposed to gradients ofpH,pO2 and nutrients. TMSs
are considered to provide a system of compact cells in a cellular
microenvironment resembling that found in vivo. In this study, we
examined the expression and function of C regulators in ovarian
TMSs to develop an in vitro model for analysing the effects of
targeted C attack against three-dimensional ovarian tumours.
MATERIALS AND METHODS
Antibodies and sera
The rat hybridoma cell line producing the YTH53.1 anti-CD59
monoclonal antibody (MAb) was kindly provided by Professor H
Waldmann (Sir William Dunn School of Pathology, University of
Oxford, UK). YTH53.1 (IgG2b) was purified from cell culture
supernatants using a Protein G Sepharose 4 Fast Flow affinity
column (Pharmacia, Uppsala, Sweden). The MAb YTH53.1 was
biotinylated by cross-linking biotin to the £-amino groups via a
long arm N-hydroxylsuccinimide ester using the biotin labelling
method ofVector Laboratories (Burlingame, CA, USA) essentially
as described (Jokiranta and Meri, 1993). Lack of activation of the
classical C pathway was examined using a Clq binding test
(Jokiranta and Meri, 1993). The mouse MAb BRIC230 (IgGI)
(anti-DAF) was a generous gift from the International Blood Group
Reference Laboratory (Bristol, UK). The mouse MAbs BRIC229
(IgG2b) (anti-CD59), J4-48 (IgGI) (anti-MCP) and aEll (IgG2a)
(anti-C5b-9) were purchased from Bioproducts Laboratories
(Elstree, UK), Serotec (Oxford, UK) and Dakopatts (Glostrup,
Denmark) respectively. A fluorescein isothiocyanate (FITC)-
conjugated goat anti-C3c MAb was purchased from Nordic
Immunological Laboratories (Tilburg, The Netherlands). The poly-
clonal antibody S2 was raised by immunizing a rabbit three times
intramuscularly with 107 heat-killed MCF7 cells (breast adenocar-
cinoma cells) (Hakulinen and Meri, 1994). When appropriate, IgG
fractions were prepared by protein G affinity chromatography
(Pharmacia). Normal human serum (NHS) was separated from
coagulated blood samples from healthy laboratory personnel,
divided into 2-ml aliquots and stored at -70°C until used.
Cell culture
The ovarian teratocarcinoma cell line PA-1 was obtained from
American Type Culture Collection (ATCC, Rockville, MD, USA).
The cells were grown in monolayers at 37°C in a humidified
atmosphere of 5% carbon dioxide in Dulbecco's modified Eagle
medium (DMEM; Gibco, Paisley, UK), supplemented with 10%
heat-inactivated fetal calf serum (FCS; Gibco), 2 mM L-glutamine
(Nord Cell, Bromma, Sweden) and antibiotics [10 units ml-1 of
penicillin (AL, Oslo, Norway) and 100 jg ml-1 of streptomycin
(Glaxo, UK)]. Cells were grown in cell culture flasks (Costar, MA,
USA) or on coverslips in chambers. Cells were detached from the
culture flasks with Versene/EDTA (Gibco), washed twice and
resuspended in phosphate-buffered saline (PBS) containing 1%
bovine serum albumin (BSA; Sigma).
Tumour microspheroids (TMSs)
TMSs ofPA-I cells were initiatedby seeding cells on 24-well plates
(Costar) coated with a thin layer of agarose [0.5% Agarose M
(Pharmacia) in distilled water]. PA-1 cells placed into growth
medium attached to one another and formed spherical cell aggre-
gates. Cell viability was regularly assessed by microscopic examin-
ation after incubation with propidium iodide (Sigma). PA-I
spheroids were grown for an average of 2 weeks and the spheroids
with diameters between 100-150 jim were selected for the experi-
ments. Some ofthe TMSs were harvested, washed and snap frozen
in isopentane precooled with liquid nitrogen for immunohistochem-
ical analysis. Fresh TMSs were used for the functional studies.
Initially, we also tried to make spheroids of the ovarian carci-
noma cell lines SK-OV-3, Caov-3 and SW626 (ATCC), but their
ability to form spheroids was poor.
Flow cytometry analysis (FCM)
PA-I cells (0.2 x 106) were incubated for 1 h on ice with different
concentrations of MAbs directed against CD59 (BRIC229), DAF
(BRIC230) or MCP (J4-48) or with the rabbit serum S2 diluted in
PBS/BSA and 5% heat-inactivated (56°C, 30 min) NHS. The cells
were washed twice in PBS/BSA and incubated on ice for 45 min
with FITC-conjugated rabbit anti-mouse Ig (Cappel, Organon
Teknika, West Chester, PA, USA) or FITC-conjugated swine anti-
rabbit Ig (Dakopatts, Glostrup, Denmark) both diluted 1:50 in
PBS/BSA. After washing twice in PBS/BSA, the cells were fixed
with 1% paraformaldehyde in PBS and kept at 4°C until analysed.
Controls included cells incubated without an idiotype-specific
mouse MAb against human B-cell receptor with reactivity with the
target cells (provided by Dr Matti Kaartinen at Haartman Institute,
Department of Bacteriology and Immunology, University of
Helsinki, Helsinki) or normal rabbit serum during the first step.
Immunofluorescence was analysed and quantified using a Becton
Dickinson FACScan 440 (San Jose, CA, USA) or a Coulter Profile
II (Coulter Electronics, Luton, UK) flow cytometer with standard
filter set ups.
Immunofluorescence microscopy
Cryostat sections of TMSs (5 jim) on gelatin-coated slides were
fixed in acetone at -20°C for 5 min. After fixation, the sections
were incubated with the MAbs BRIC229, BRIC230 and J4-48
(1 jig ml-') or with S2 (dilution 1:100) in a moist chamber
according to the immunofluorescence labelling protocol described
above. After the final washes in PBS/BSA, the sections were
mounted in Mowiol (Heimer and Taylor, 1974). A Leitz micro-
scope (Heidelberg, Germany) equipped with standard fluorescein
optics was used for the immunofluorescence analysis.
PA-1 cells grown on coverslips were stained similarly, except
that in the standard assay the specimens were not fixed in acetone
before the staining procedure.
Penetration of antibodies into TMSs
TMSs on agarose-coated plates were incubated with 10 jig ml-' of
BRIC229 or heat-inactivated S2 (dilution 1:50) in growth medium
for 18 h at 37°C in a humidified atmosphere with 5% carbon
dioxide. A mouse monoclonal antibody with no known reactivity
with the PA-I cells and normal rabbit serum were used as controls.
After washing (2 x 30 min, 37°C) in PBS, the TMSs were incu-
bated for another 18 h with the FITC-conjugated F(ab')2 rabbit
anti-mouse Ig (Dakopatts) or FITC-conjugated F(ab')2 donkey
anti-rabbit Ig (Jackson Immunoresearch Laboratories, PA, USA).
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Figure 1 Immunofluorescence examination of complement regulator expression on cultured PA-1 cells (A-D) and cryostat sections of PA-1 cells grown in
tumour microspheroids (E-H). Specimens were stained for MCP (A and E), DAF (B and F) and CD59 (C and G) with the MAbs J4-48, BRIC230 and BRIC229
respectively. Controls were stained with an unrelated mouse MAb (D and H). A-D, x300; E-H, x40
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Figure 2 Flow cytometric analysis of MCP, DAF and CD59 on PA-1 cells in
suspension. The cells were labelled with anti-MCP, anti-DAF or anti-CD59
MAb or with a control MAb (curve on the left in each panel) followed by FITC-
conjugated rabbit anti-mouse Ig
Afterwashing, theTMSs werefixed in 1% paraformaldehyde for2 h
andanalysed on aBioRadMRC 1000confocallaserscanning micro-
scope, CLSM (Bio-Test, Rygge, Norway) with a crypton-argon
laser. TMSs were scanned in a plane 50-100 jm into the spheroid
using the 488 nmexcitation line. Alternatively, thefixedTMSs were
snap frozen, sectioned and examined in a Leitz immunofluorescence
microscope.
Deposition of C3 and C5b-9 on PA-1 cells after
C activation
PA-l cells (2 x I0) in suspension were incubated for 1 h on ice in
10% heat-inactivated S2 diluted in PBS/BSA. After washing twice
in Veronal-buffered saline, pH 7.4 (VBS), the PA-1 cells were
further incubated with 100 jl of 10% NHS diluted in VBS for
30 min at 37°C. In controls, the classical and alternative C pathways
were blocked by adding 0.01 M EDTA to the reaction mixture. After
washing three times in PBS/BSA, the cells were immunostained
with the anti-C5b-9 MAb aEl 1 (2 jig ml-') or with the FITC-conju-
gated goat anti-humanC3c (diluted 1:40) andprocessed for FCM as
described above. Negative controls includedunsensitized cells incu-
bated with NHS. TMSs were examined in a similar fashion, except
that the TMSs were incubated for 18 h with S2 during the sensitiza-
tion step and that C depositions were analysed by immunofluores-
cence staining ofcryostat sections ofTMSs.
C-mediated lysis of PA-1 cells
Washed TMSs grown for 2 weeks were labelled with 100 jCi
"1chromium (51Cr; Na51CrO4; Amersham, UK) (approximately 500
TMSs in 1 ml of DMEM) for 12 h at 370C, with occasional
shaking. This incubation time has earlier been shown to lead to
efficient uptake of 5'Cr into the TMSs (Jaaskelainen et al, 1989).
To remove unbound 5lCr, the TMSs were washed twice in DMEM
and incubated for a further 30 min at 370C in 500 pl of DMEM,
before repeating the washing procedure. During labelling the
TMSs were incubated simultaneously withappropriate dilutions of
antibodies (S2 and/orbiotinylated YTH53.1). Final concentrations
of reagents (given in 50 gl of DMEM) are indicated in the figure
legends. In controls, the individual effects of each of the reagents
were examined by replacing them with equivalent amounts of
DMEM. TMSs (approximately 20-30 pertube in 50 pl ofDMEM)
were then incubated with 25% NHS (in a final volume of 200 ul)
for 30 min at 370C. After centrifugation (500g for 5 min), 100 pl
samples of the supernatants were carefully removed and counted
in a gammacounter. 5'Cr-release in the absence of antibodies was
taken as a background (range: 0.5-1.0% of total label incorpor-
ated) and release by 0.1% Nonidet P40 (BDH Laboratories
Supplies, Poole, UK) as total release ofradioactivity. During a 30-
min incubation, 0.1% NP40 released 8% oftotal 51Crincorporated.
Cell lysis in the TMSs was determined as percentage of antibody
plus complement-induced 51Cr release into the supernatant.
Examination of C-mediated lysis of PA-1 cells in suspension was
performed in a 5tCr-release assay as described earlier (Hakulinen
and Meri, 1994). A total of5 x 107 cells were labelled with 25 ,uCi
of51Cr in 150 1l of DMEM. After washes and a 30-min reincuba-
tion to release loosely bound 51Cr, the cells were aliquoted (105
cells pertube) forthe 5'Cr-release assay, which was performed in a
similar way to that described for TMSs above.
RESULTS
Spheroid formation and growth
Aggregates ofPA-I cells were observed as early as 2-3 days after
seeding on agar gels. Large spheroids ofdensely packed cells with
aregularround shape were formed atthe end ofthe first week. The
viability of the cells within the spheroids was repeatedly checked
by staining with propidium iodide, which showed that only a few
nuclei, if any, outside a central core adsorbed the dye.
Expression of complement regulatory proteins on PA-1
cells and spheroids
PA-l cells grown on coverslips showed a membranous staining
for both MCP and CD59 with the J4-48 and BRIC229 antibodies
respectively (Figure 1A and C). No reactivity was seen with
the anti-DAF MAb BRIC230 or the control mouse MAb (Figure
lB and D).
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Figure 3 Confocal microscopy analysis of binding of antibodies to the TMSs. TMSs were cultured on agar-coated plates in the presence of the anti-CD59 MAb
BRIC229 (A) or the polyclonal rabbit antibody S2 (C) (18 h, 37°C) followed by FlTC-conjugated rabbit anti-mouse 19 or FlTC-conjugated donkey anti-rabbit 19
(18 h, 37°C). TMSs were fixed in paraformaldehyde (1%, 2 h) and analysed by confocal laser scanning microscopy. Controls were cultured with an unrelated
mouse MAb (B) or normal rabbit serum (D) in the first step. BRIC229 bound to the outermost 4 or 5 cell layers (A), whereas S2 bound very strongly to the outer
7 or 8 cell layers, more weakly to the next 2 or 3 cell layers and not to the most centrally located cells (C)
FCM was used to further analyse the expression ofcomplement
regulatory proteins on the surface PA-1 cells in suspension. These
experiments showed that CD59 and MCP were expressed on the
surface of the cells. The widths of the unimodal fluorescence
profiles forboth molecules were narrow, and more than 90% ofthe
cells were stained. The cells were not, or only very weakly, stained
with the anti-DAF MAb BRIC230 (Figure 2).
Sections of TMSs showed strong staining for both MCP and
CD59, with a homogeneous pattern throughout the TMSs. All cells
showed a prominent circumferential linear membrane staining
(Figure IE and G). The staining pattern for DAF was different.
Distinct foci in the outer rim stained positive with the BRIC230
(Figure IF). The fluorescence was located to the surface
membrane of the cells. TMSs incubated with the control MAb
during the first incubation step were not stained (Figure 1H).
Binding of the polyclonal S2 antibody to PA-1 cells and
spheroids
PA-1 cells grown on coverslips showed a strong membranous
staining for the polyclonal S2 antibody. FCM confirmed this and
showed a strong reactivity of S2 with the cells. The width of the
unimodal fluorescence profile was broad, and 99.1% of the cells
were positive for S2 IgG with a mean fluorescence index of 629.7
(background 10.9). Staining of sections ofTMSs with the S2 anti-
body also showed a strong fluorescence. The staining pattern was
homogeneous, and all cells showed a prominent circumferential
linear membrane staining. Cells incubated with the preimmune
rabbit serum during the first incubation step showed no staining
(data not shown).
Access of antibodies to PA-1 cells in the spheroids
Incubation of fresh TMSs for 18 h with the BRIC229 anti-CD59
MAb only stained the outermost 4 or 5 cell layers when analysed by
the confocal laser scanning microscopy. The antibody gave a clear
and distinct surface membrane staining. The more centrally located
cell layers showed no staining. There was no transition zone between
the positively and negatively stained areas (Figure 3A). After expos-
ure of the TMSs to S2 as many as 7 or 8 outer cell layers showed a
strong positive staining. The next 2 or 3 more centrally located cell
layers showed a weaker staining, thereby constituting a transition
zone. The most centrally located cells were not stained (Figure 3C).
These findings were confirmed by immunofluorescence microscopy
of cryostat sections of TMSs subjected to the same penetration
experiments (data not shown). Control TMSs incubated with an irrel-
evant MAb or normal rabbit serum during the first incubation step
showed no (Figure 3B) or weak, non-specific (Figure 3D) staining.
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Figure 4 Flow cytometric and scatter profile analysis of antibody-induced deposition of C3 (A and C) and C5b-9 (D and F) on PA-1 cells in suspension. The
cells were sensitized with the polyclonal rabbit antibody S2 and incubated with 100% NHS (30 min, 370C) in the presence (M; B and E) or absence (El; C and F)
of 0.01 M EDTA. Cells were stained with FITC-conjugated goat anti-C3c Ab (A-C) or with the aEll anti-C5b-9 MAb followed by FITC-conjugated rabbit anti-
mouse Ig (D-F). C3 and C5b-9 were detected on 95% and 60% of the PA-1 cells in suspension respectively
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Figure 5 Immunofluorescence analysis of antibody-induced deposition of C3 and C5b-9 on PA-1 TMSs. TMSs were sensitized with the polyclonal rabbit
antibody S2 and incubated with 10% NHS (30 min, 370C) in the absence (A and C) or presence (B and D) of 0.01 M EDTA. Cryostat sections of TMSs were
stained with FITC-conjugated anti-C3c (A and B) or with the aEll anti-C5b-9 MAb followed by FITC-conjugated rabbit anti-mouse Ig (C and D). Note deposition
of both C3 and C5b-9 on the outer cell layers of the TMSs
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tested tumour antigen-reactive mouse MAbs (Bj0rge et al, 1996)
activated C on the surface ofPA-I cells.
To see if C components could penetrate into spheroids, fresh
TMSs were sensitized with S2 for 18 h and thereafter treated with
NHS (30 min, 37°C). Cryostat sections of the spheroids stained
positive for both C3c and C5b-9. The staining patterns were
similar and, interestingly, only the outer 2-5 layers were stained
(Figure 5). No binding of the anti-C3c or anti-C5b-9 MAb was
seen to cells in suspension or to TMSs that were not sensitized
with the S2 antibody. The presence of EDTA in the incubation
mixture also prevented C3c and C5b-9 deposition on S2-sensitized
cells and spheroids.
Sensitivity of PA-1 cells and spheroids to C-mediated
cytotoxicity
The cytotoxic effect ofhuman C and the functional significance of
CD59 in protecting PA-1 cells against C-mediated damage was
examined using cells in suspension and in TMSs. PA-1 cells in
suspension sensitized with the polyclonal rabbit antibody S2
showed a dose-dependent vulnerability to C-mediatedlysis (Figure
0.3 6A). Using a saturating concentration ofS2, approximately 65% of
the cells were killed in the presence of 25% NHS during a 30-min
incubation at 37°C. Ten per cent NHS resulted in the killing of
17% oftarget cells. In the presence of25% NHS and 25 gg ml-l of
the biotinylated anti-CD59 YTH53.1, an average of 88% of PA-1
cells were killed. In comparison, PA-I cells in TMSs were found to
be resistant to C-mediated cytotoxicity (Figure 6B). After sensiti-
zation with S2, in the presence of 25% NHS for 30 min, approxi-
mately 4% of the cells in the TMSs were lysed, while 8% of the
cells in the spheroids were lysed when the biotinylated YTH53.1
MAb was added to the reaction mixture (release of 51Cr by 0.1%
NP40 was taken as total lysis). In the absence of the sensitizing
rabbit antibody, no lysis occurred in the two cell systems with the
combination ofbiotinylated YTH53.1 MAb and NHS.
DISCUSSION
20 -
S2 + B-YTH53.1
2
0 0.1 0.2
Antibody dilution
Figure 6 Complement-mediated killing of PA-1 cells in suspension (A) or
TMSs (B) in the presence (0) or absence (0) of biotinylated YTH53.1 (anti-
CD59). 5'Cr-labelled cells and TMSs (50 ,l) were sensitized with different
amounts of the polyclonal rabbit antibody S2 (50 gl) in the presence or
absence of B-YTH53.1 (25 9g ml-1) and exposed to NHS (25%) in final
volume of 200 gl (370C, 30 min). Cell lysis (mean ± s.d.) was quantified as
release of 51Cr into the medium. Significantly, more PA-1 cells in suspension
were killed in the presence than absence of B-YTH53.1 (*P< 0.05). Under
similar conditions, the PA-1 cells in spheroids were resistant to C lysis
C3 and C5b-9 on PA-1 cells and spheroids after
C activation
After activation ofthe classical pathway ofC (10% serum) by S2,
C3 and CSb-9 were detected on more than 95% and 60% of the
PA-1 cells in suspension respectively (Figure 4). None of the
The experiments described in this paper demonstrate that cells in
suspension and cells growing in multicellular spheroids differ in
their ability to resist C-mediated cytotoxicity. Cells growing in
TMSs were much more difficult to kill by C than cells in suspen-
sion. This phenomenon was at least partly dependent on differ-
ences in the binding of C-activating antibodies to cells in the two
systems and possibly on acquisition of an increase in C resistance
when the tumour cells are grown in TMSs.
In line with our recent study, we found MCP and CD59 expres-
sion, but no or only negligible DAF expression, on PA-1 cells in
suspension and on cells growing in monolayers (Bj0rge et al,
1996). Similarly, PA-I cells growing in TMSs also expressed MCP
and CD59, and the intensity of expression was homogeneous
throughout the TMSs. Interestingly, DAF was also expressed on
the PA-1 TMSs. The location ofDAF-expressing cells was rather
distinct, as only foci in the outer layers in the TMSs expressed
DAF. Differences between spheroids and monolayers in the
expression of integrins (Brackman, 1995), extracellular matrix
components (Brackman, 1995), growth factors (Ness et al, 1994)
and growth factor receptors (Ness et al, 1994) have been observed
earlier. A possible explanation for these differences is the influ-
ence ofthe distinct cellular microenvironment present in the spher-
oids (Sutherland, 1988; Carlsson and Nederman, 1992). PA-1 is a
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teratocarcinoma cell line that can differentiate into different germ
cell layers when growing on non-adhesive surfaces (Zeuthen et al,
1980). On their surface, the cell aggregates contain endoderm-like
cells that surround the inner cell mass. As DAF is a marker of
early differentiation (Holmes et al, 1992), the induction of its
expression could alternatively be explained by the differential
organization ofcells in the TMSs.
Although both S2 and BRIC229 stained sections of TMSs
homogeneously, confocal microscopy showed that these anti-
bodies had only a limited ability to penetrate into live spheroids.
These findings were confirmed by ordinary immunofluorescence
microscopy on cryostat sections to exclude experimental caveats
inherent in the staining protocol used for the confocal laser scan-
ning microscopy analysis. The S2 rabbit IgG penetrated deeper
into the spheroids than BRIC229. As it has been predicted that
low-affinity antibodies penetrate into tumours more readily than
high-affinity antibodies (Fujimori et al, 1989; Langmuir et al,
1992), the difference between BRIC229 and S2 is probably
because BRIC229 is a high-affinity MAb (Fletcher et al, 1992),
while the S2 IgG probably contains antibodies with different
affinities against different antigens. Lack of antibody penetration
into the core ofTMSs probably reflects the existence oftight inter-
cellularjunctions between the cells (Jain, 1988). In addition, cells
in the spheroids may have synthesized a glycocalyx (Riethmuller
et al, 1993) or a basement membrane-like structure (Zeuthen et al,
1980) that also restrict the access of antibodies into the deeper
layers ofthe TMSs.
Antibody-mediated C activation on PA-1 cells in suspension
induced C deposition on nearly all the cells. A similar C attack on
the PA-1 TMSs resulted only in deposition of C factors on the
outer cell layers of the aggregates. In cell killing experiments, the
PA-1 cells were sensitized with the S2 polyclonal antibody. After
screening of many monoclonal antibodies, two were found that
bound to the PA-I cells and activated C (C241 against CAl9-9 and
Ma552 against MUC-1). Unfortunately, the binding of these anti-
bodies to PA-I cells was too weak to lead to efficient C activation.
S2-sensitized PA-I cells in suspension were shown to be C treated,
as almost 65% of the cells were killed after C activation.
Neutralization ofCD59 enhanced cell killing to more than 85%. In
contrast, PA-1 cells growing in TMSs were C resistant; less than
10% ofthe cells were killed by C. Blocking ofCD59 with biotiny-
lated YTH53.1 reduced the resistance of the TMSs to C-mediated
lysis only very moderately. The spheroids remained resistant even
when higher concentrations of both biotinylated YTH53.1 and
NHS were used (data not shown). An earlier study by Buckman et
al (1982) obtained similar results by showing that a monoclonal
antibody, Fib-75, activated complement on epithelial tumour cells
and killed the cells when they were in suspension but not when
they were in large clumps.
The difference in PA-1 sensitivity to C lysis between the two
systems could be partly determined by the variable access of the
C-activating antibodies to the tumour cells. Spheroid tissue may
prevent deeper penetration of C until the most superficial cell
layers have become damaged, and even after cell damage a barrier
of some degree may remain. When high-affinity antibodies are
used they may bind avidly to the outermost surface and do not
necessarily penetrate deeper into the TMSs. Despite the fact that
antibodies bound to TMSs and activated C, no significant C lysis
was observed. Recently, we noticed that DAF expression was
inversely correlated with the ovarian tumour cells' vulnerability to
C-mediated killing (Bj0rge et al, 1996). Induced expression of
DAF on cells localized at the surface of the TMSs, could also
partly explain the increased C resistance ofthe cells. Other mech-
anisms, such as rapid depletion ofC activity or induced resistance
to C attack (Morgan, 1989; Reiter et al, 1992), may also
contribute. Further studies are required to see if killing of tumour
cells in spheroids can be enhanced by prolonged or repeated C
treatment or by employing the antibody-dependent cellular cyto-
toxicity (ADCC) effector mechanism to the tumour cell killing. It
is anticipated that under in vivo conditions ADCC will play an
important role in immune attack against tumour cells.
The approach ofusing MAbs and the C system as an effector to
kill tumour cells may be an attractive adjuvant immunotherapeutic
alternative (Chapman et al, 1992; Riethmuller et al, 1993).
Attempts to use unconjugated C-activating MAbs in the therapy of
solid tumours have therefore been tried (Houghton et al, 1985;
Goodman et al, 1990; Riethmuller et al, 1993; Rubin, 1993).
Although the MAbs bind to the tumour cells in vivo (Houghton et
al, 1985; Rubin, 1993) and mediate local C deposition (Houghton
et al, 1985), the therapeutic efficiency is limited (Houghton et al,
1985; Riethmuller and Johnson, 1992; Riethmuller et al, 1993;
Rubin, 1993) and correlates negatively with the volume of the
tumour mass (Riethmuller et al, 1993). Barriers for free access of
MAbs and C to the tumour cells and the existence of C resistance
mechanisms may limit the success rate (Riethmuller et al, 1993).
However, in vitro tests have shown that itis possible to kill tumour
cells in suspension using appropriate MAbs and C in combination
with targeted neutralization of membrane regulators of comple-
ment (Cheung et al, 1988; Bj0rge et al, 1994; Hakulinen and Meri,
1994; Junnikkala et al, 1994; Brasoveanu et al, 1995; Maenpaa et
al, 1996). The in vivo protocols forthis type ofimmunotherapeutic
analysis therefore have to be refined for effective destruction of
tumour cells in three-dimensional structures.
Ovarian cancer represents a good candidate for MAb tumour
therapy (Rubin, 1993). MAbs can be applied by both the intraperi-
toneal and intravenous route. Ifthe limitations ofMAb penetration
and resistance to C can be overconie, the clinical use of MAbs in
the management ofovarian cancer could enter a new era.
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